Sort
82,697 grants matching “vaccine development”
Resource for Molecular Imaging Agents in Precision Medicine
$1,203,878Martin G Pomper · Johns Hopkins University · P41 · FY2019 · EB
Ebola Vaccine Development
$1,203,749Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Resource for Molecular Imaging Agents in Precision Medicine
$1,203,600Martin G Pomper · Johns Hopkins University · P41 · FY2020 · EB
A Global Research Resource for Human Tuberculosis
$1,203,595Adrie Jc Steyn · University Of Alabama At Birmingham · R24 · FY2025 · AI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine
$1,203,584Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2020 · AI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine
$1,203,246Matthias Johannes Schnell · Thomas Jefferson University · R01 · FY2015 · AI
Comprehensive Minority and Health Disparities Research Center - Phase III
$1,203,184Mona N. Fouad · University Of Alabama At Birmingham · P60 · FY2016 · MD
Development of a novel adjuvant for vaccine sparing
$1,203,147Sara Lustigman · New York Blood Center · R01 · FY2014 · AI
Product Development and Manufacture
$1,203,014Jennifer L Nelms · Geovax, Inc. · U19 · FY2007 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,202,956Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
HIVRAD: Structural approaches to vaccine development
$1,202,907Dana-Farber Cancer Institute · P01 · FY2002 · AI
Core 3 - Immunobiology Core
$1,202,642Derek Wilson Cain · Duke University · U54 · FY2023 · AI
Closing Research Gaps in Antiretroviral Treatment for Pregnant Women and Infants Living with HIV
$1,202,581Roger L Shapiro · Harvard School Of Public Health · P01 · FY2023 · HD
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2
$1,202,440Michael S. Diamond · Washington University · R01 · FY2022 · AI
A dual vaccine strategy against filovirus infection
$1,202,422Richard W Compans · Emory University · R01 · FY2015 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies
$1,202,174Luis Manuel Branco · Zalgen Labs, Llc · R01 · FY2021 · AI
Discovery and Translational Core Services
$1,201,789Gerald A Beltz · Harvard Medical School · U19 · FY2015 · AI
Reactions And Immunochemistry Of Carbohydrates
$1,201,120Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Developmental and Mentoring Core
$1,201,004Ingrid Valerie Bassett · Harvard University · P30 · FY2019 · AI
New Jersey Alliance for Clinical Translational Science: NJ ACTS
$1,200,946Reynold Alexander Panettieri · Rutgers Biomedical/Health Sciences-Rbhs · UL1 · FY2021 · TR
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
$1,200,711Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2022 · AI
REGULATION OF ANTI-TUMOR IMMUNITY
$1,200,459Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2009 · CA
Antigen Processing And Presentation In The Intestine
$1,200,282Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
$1,200,245Elias Sayour · University Of Florida · R01 · FY2025 · CA
NIAID Preclinical Development Support
$1,200,124Fred Mack · Advanced Bioscience Laboratories, Inc. · N01 · FY2017 · AI